Does the media prefer TNDM or SGHT?

In the previous week, Tandem Diabetes Care had 7 more articles in the media than Sight Sciences. MarketBeat recorded 8 mentions for Tandem Diabetes Care and 1 mentions for Sight Sciences. Tandem Diabetes Care's average media sentiment score of 0.81 beat Sight Sciences' score of 0.00 indicating that Tandem Diabetes Care is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tandem Diabetes Care 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sight Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor SGHT or DRTS?

In the previous week, Alpha Tau Medical had 9 more articles in the media than Sight Sciences. MarketBeat recorded 10 mentions for Alpha Tau Medical and 1 mentions for Sight Sciences. Alpha Tau Medical's average media sentiment score of 0.29 beat Sight Sciences' score of 0.00 indicating that Alpha Tau Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sight Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alpha Tau Medical 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, SGHT or BVS?

Bioventus has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sight Sciences $77.36M 3.54 -$38.43M -$0.71 N/A Bioventus $576.30M 1.68 $22.73M $0.41 28.24

Is SGHT or BVS more profitable?

Bioventus has a net margin of 4.94% compared to Sight Sciences' net margin of -46.83%. Bioventus' return on equity of 29.97% beat Sight Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Sight Sciences -46.83% -52.34% -28.49% Bioventus 4.94% 29.97% 9.52%

Does the media refer more to SGHT or BVS?

In the previous week, Bioventus had 2 more articles in the media than Sight Sciences. MarketBeat recorded 3 mentions for Bioventus and 1 mentions for Sight Sciences. Bioventus' average media sentiment score of 1.10 beat Sight Sciences' score of 0.00 indicating that Bioventus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sight Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bioventus 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, INMD or SGHT?

InMode has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InMode $370.49M 2.38 $93.83M $1.36 11.29 Sight Sciences $77.36M 3.54 -$38.43M -$0.71 N/A

Is INMD or SGHT more profitable?

InMode has a net margin of 23.27% compared to Sight Sciences' net margin of -46.83%. InMode's return on equity of 13.47% beat Sight Sciences' return on equity. Company Net Margins Return on Equity Return on Assets InMode 23.27% 13.47% 11.95% Sight Sciences -46.83% -52.34% -28.49%

Does the media prefer INMD or SGHT?

In the previous week, InMode had 3 more articles in the media than Sight Sciences. MarketBeat recorded 4 mentions for InMode and 1 mentions for Sight Sciences. InMode's average media sentiment score of 0.11 beat Sight Sciences' score of 0.00 indicating that InMode is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InMode 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sight Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Sight Sciences (SGHT) Competitors

$5.04 +0.01 (+0.10%)

As of 09:53 AM Eastern

Compare

SGHT vs. TNDM, DRTS, BVS, AVR, and INMD

Should you buy Sight Sciences stock or one of its competitors? MarketBeat compares Sight Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sight Sciences include Tandem Diabetes Care (TNDM), Alpha Tau Medical (DRTS), Bioventus (BVS), Anteris Technologies Global (AVR), and InMode (INMD). These companies are all part of the "medical equipment" industry.

How does Sight Sciences compare to Tandem Diabetes Care?

Tandem Diabetes Care (NASDAQ:TNDM) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

55.5% of Sight Sciences shares are owned by institutional investors. 2.1% of Tandem Diabetes Care shares are owned by insiders. Comparatively, 30.4% of Sight Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Tandem Diabetes Care has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market. Comparatively, Sight Sciences has a beta of 2.38, meaning that its stock price is 138% more volatile than the broader market.

In the previous week, Tandem Diabetes Care had 7 more articles in the media than Sight Sciences. MarketBeat recorded 8 mentions for Tandem Diabetes Care and 1 mentions for Sight Sciences. Tandem Diabetes Care's average media sentiment score of 0.81 beat Sight Sciences' score of 0.00 indicating that Tandem Diabetes Care is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tandem Diabetes Care	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sight Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tandem Diabetes Care has a net margin of -9.20% compared to Sight Sciences' net margin of -46.83%. Sight Sciences' return on equity of -52.34% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-9.20%	-53.88%	-7.88%
Sight Sciences	-46.83%	-52.34%	-28.49%

Tandem Diabetes Care presently has a consensus target price of $28.93, indicating a potential upside of 59.81%. Sight Sciences has a consensus target price of $8.25, indicating a potential upside of 63.69%. Given Sight Sciences' higher possible upside, analysts plainly believe Sight Sciences is more favorable than Tandem Diabetes Care.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	1 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.45
Sight Sciences	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

Sight Sciences has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Sight Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$1.01B	1.22	-$204.71M	-$1.40	N/A
Sight Sciences	$77.36M	3.54	-$38.43M	-$0.71	N/A

Summary

Sight Sciences beats Tandem Diabetes Care on 9 of the 17 factors compared between the two stocks.

How does Sight Sciences compare to Alpha Tau Medical?

Sight Sciences (NASDAQ:SGHT) and Alpha Tau Medical (NASDAQ:DRTS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

In the previous week, Alpha Tau Medical had 9 more articles in the media than Sight Sciences. MarketBeat recorded 10 mentions for Alpha Tau Medical and 1 mentions for Sight Sciences. Alpha Tau Medical's average media sentiment score of 0.29 beat Sight Sciences' score of 0.00 indicating that Alpha Tau Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sight Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alpha Tau Medical	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

55.5% of Sight Sciences shares are held by institutional investors. Comparatively, 2.7% of Alpha Tau Medical shares are held by institutional investors. 30.4% of Sight Sciences shares are held by insiders. Comparatively, 39.5% of Alpha Tau Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Sight Sciences presently has a consensus price target of $8.25, indicating a potential upside of 63.69%. Alpha Tau Medical has a consensus price target of $12.60, indicating a potential downside of 6.46%. Given Sight Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe Sight Sciences is more favorable than Alpha Tau Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Alpha Tau Medical	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

Sight Sciences has higher revenue and earnings than Alpha Tau Medical. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Sight Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sight Sciences	$77.36M	3.54	-$38.43M	-$0.71	N/A
Alpha Tau Medical	N/A	N/A	-$42.63M	-$0.67	N/A

Alpha Tau Medical has a net margin of 0.00% compared to Sight Sciences' net margin of -46.83%. Sight Sciences' return on equity of -52.34% beat Alpha Tau Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-46.83%	-52.34%	-28.49%
Alpha Tau Medical	N/A	-73.23%	-52.90%

Sight Sciences has a beta of 2.38, suggesting that its stock price is 138% more volatile than the broader market. Comparatively, Alpha Tau Medical has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market.

Summary

Sight Sciences beats Alpha Tau Medical on 10 of the 15 factors compared between the two stocks.

How does Sight Sciences compare to Bioventus?

Sight Sciences (NASDAQ:SGHT) and Bioventus (NASDAQ:BVS) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 62.9% of Bioventus shares are owned by institutional investors. 30.4% of Sight Sciences shares are owned by insiders. Comparatively, 33.5% of Bioventus shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Bioventus had 2 more articles in the media than Sight Sciences. MarketBeat recorded 3 mentions for Bioventus and 1 mentions for Sight Sciences. Bioventus' average media sentiment score of 1.10 beat Sight Sciences' score of 0.00 indicating that Bioventus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sight Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bioventus	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sight Sciences has a beta of 2.38, suggesting that its share price is 138% more volatile than the broader market. Comparatively, Bioventus has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

Sight Sciences currently has a consensus target price of $8.25, suggesting a potential upside of 63.69%. Bioventus has a consensus target price of $14.75, suggesting a potential upside of 27.37%. Given Sight Sciences' higher possible upside, analysts clearly believe Sight Sciences is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Bioventus has a net margin of 4.94% compared to Sight Sciences' net margin of -46.83%. Bioventus' return on equity of 29.97% beat Sight Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-46.83%	-52.34%	-28.49%
Bioventus	4.94%	29.97%	9.52%

Bioventus has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sight Sciences	$77.36M	3.54	-$38.43M	-$0.71	N/A
Bioventus	$576.30M	1.68	$22.73M	$0.41	28.24

Summary

Bioventus beats Sight Sciences on 13 of the 17 factors compared between the two stocks.

How does Sight Sciences compare to Anteris Technologies Global?

Anteris Technologies Global (NASDAQ:AVR) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Sight Sciences has higher revenue and earnings than Anteris Technologies Global. Sight Sciences is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anteris Technologies Global	$1.91M	418.92	-$94.14M	-$2.23	N/A
Sight Sciences	$77.36M	3.54	-$38.43M	-$0.71	N/A

Anteris Technologies Global currently has a consensus target price of $16.00, suggesting a potential upside of 94.65%. Sight Sciences has a consensus target price of $8.25, suggesting a potential upside of 63.69%. Given Anteris Technologies Global's stronger consensus rating and higher probable upside, equities research analysts plainly believe Anteris Technologies Global is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anteris Technologies Global	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Sight Sciences	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

Sight Sciences has a net margin of -46.83% compared to Anteris Technologies Global's net margin of -5,148.78%. Sight Sciences' return on equity of -52.34% beat Anteris Technologies Global's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anteris Technologies Global	-5,148.78%	-124.76%	-101.21%
Sight Sciences	-46.83%	-52.34%	-28.49%

Anteris Technologies Global has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market. Comparatively, Sight Sciences has a beta of 2.38, indicating that its share price is 138% more volatile than the broader market.

55.5% of Sight Sciences shares are held by institutional investors. 4.5% of Anteris Technologies Global shares are held by company insiders. Comparatively, 30.4% of Sight Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Sight Sciences had 1 more articles in the media than Anteris Technologies Global. MarketBeat recorded 1 mentions for Sight Sciences and 0 mentions for Anteris Technologies Global. Anteris Technologies Global's average media sentiment score of 0.40 beat Sight Sciences' score of 0.00 indicating that Anteris Technologies Global is being referred to more favorably in the media.

Company	Overall Sentiment
Anteris Technologies Global	Neutral
Sight Sciences	Neutral

Summary

Sight Sciences beats Anteris Technologies Global on 11 of the 16 factors compared between the two stocks.

How does Sight Sciences compare to InMode?

InMode (NASDAQ:INMD) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

InMode currently has a consensus price target of $16.00, indicating a potential upside of 4.17%. Sight Sciences has a consensus price target of $8.25, indicating a potential upside of 63.69%. Given Sight Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Sight Sciences is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sight Sciences	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

InMode has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMode	$370.49M	2.38	$93.83M	$1.36	11.29
Sight Sciences	$77.36M	3.54	-$38.43M	-$0.71	N/A

In the previous week, InMode had 3 more articles in the media than Sight Sciences. MarketBeat recorded 4 mentions for InMode and 1 mentions for Sight Sciences. InMode's average media sentiment score of 0.11 beat Sight Sciences' score of 0.00 indicating that InMode is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMode	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sight Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

68.0% of InMode shares are owned by institutional investors. Comparatively, 55.5% of Sight Sciences shares are owned by institutional investors. 6.9% of InMode shares are owned by insiders. Comparatively, 30.4% of Sight Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

InMode has a net margin of 23.27% compared to Sight Sciences' net margin of -46.83%. InMode's return on equity of 13.47% beat Sight Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMode	23.27%	13.47%	11.95%
Sight Sciences	-46.83%	-52.34%	-28.49%

InMode has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market. Comparatively, Sight Sciences has a beta of 2.38, suggesting that its share price is 138% more volatile than the broader market.

Summary

InMode beats Sight Sciences on 10 of the 16 factors compared between the two stocks.

Get Sight Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGHT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGHT vs. The Competition

Export

Metric	Sight Sciences	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$273.68M	$7.42B	$6.89B	$12.28B
Dividend Yield	N/A	1.32%	2.67%	9.39%
P/E Ratio	-7.10	49.51	27.07	23.95
Price / Sales	3.54	49.42	519.31	90.33
Price / Cash	N/A	26.91	26.68	47.25
Price / Book	4.17	6.96	10.62	6.14
Net Income	-$38.43M	$162.27M	$3.60B	$331.74M
7 Day Performance	-0.20%	-0.45%	-1.26%	-1.82%
1 Month Performance	-4.55%	-1.58%	1.07%	-1.45%
1 Year Performance	46.94%	6.48%	23.63%	16.32%

Sight Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGHT Sight Sciences	3.1681 of 5 stars	$5.04 +0.1%	$8.25 +63.9%	+44.0%	$274.17M	$77.36M	N/A	210
TNDM Tandem Diabetes Care	2.992 of 5 stars	$15.54 -4.4%	$29.13 +87.4%	+22.5%	$1.11B	$1.01B	N/A	2,500	Positive News Gap Down
DRTS Alpha Tau Medical	1.5588 of 5 stars	$12.34 +1.3%	$12.60 +2.1%	+343.1%	$1.10B	N/A	N/A	80
BVS Bioventus	4.4195 of 5 stars	$11.56 -4.2%	$14.75 +27.6%	+85.0%	$1.01B	$576.30M	28.20	1,200
AVR Anteris Technologies Global	2.877 of 5 stars	$8.95 -4.4%	$16.00 +78.8%	+169.5%	$911.12M	$1.91M	N/A	138

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGHT) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sight Sciences (SGHT) Competitors

SGHT vs. TNDM, DRTS, BVS, AVR, and INMD

How does Sight Sciences compare to Tandem Diabetes Care?

Summary

How does Sight Sciences compare to Alpha Tau Medical?

Summary

How does Sight Sciences compare to Bioventus?

Summary

How does Sight Sciences compare to Anteris Technologies Global?

Summary

How does Sight Sciences compare to InMode?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGHT vs. The Competition

Sight Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sight Sciences (SGHT) Competitors

SGHT vs. TNDM, DRTS, BVS, AVR, and INMD

How does Sight Sciences compare to Tandem Diabetes Care?

Do institutionals & insiders believe in TNDM or SGHT?

Which has more volatility and risk, TNDM or SGHT?

Does the media prefer TNDM or SGHT?

Is TNDM or SGHT more profitable?

Do analysts prefer TNDM or SGHT?

Which has preferable valuation and earnings, TNDM or SGHT?

Summary

How does Sight Sciences compare to Alpha Tau Medical?

Does the media favor SGHT or DRTS?

Do institutionals and insiders hold more shares of SGHT or DRTS?

Do analysts prefer SGHT or DRTS?

Which has higher valuation and earnings, SGHT or DRTS?

Is SGHT or DRTS more profitable?

Which has more risk & volatility, SGHT or DRTS?

Summary

How does Sight Sciences compare to Bioventus?

Do insiders & institutionals have more ownership in SGHT or BVS?

Does the media refer more to SGHT or BVS?

Which has more risk and volatility, SGHT or BVS?

Do analysts prefer SGHT or BVS?

Is SGHT or BVS more profitable?

Which has stronger valuation and earnings, SGHT or BVS?

Summary

How does Sight Sciences compare to Anteris Technologies Global?

Which has preferable earnings & valuation, AVR or SGHT?

Do analysts recommend AVR or SGHT?

Is AVR or SGHT more profitable?

Which has more volatility and risk, AVR or SGHT?

Do institutionals & insiders have more ownership in AVR or SGHT?

Does the media prefer AVR or SGHT?

Summary

How does Sight Sciences compare to InMode?

Do analysts recommend INMD or SGHT?

Which has higher earnings & valuation, INMD or SGHT?

Does the media prefer INMD or SGHT?

Do institutionals & insiders believe in INMD or SGHT?

Is INMD or SGHT more profitable?

Which has more risk and volatility, INMD or SGHT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGHT vs. The Competition

Sight Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools